Skip to main content

Zachary Conrad Hartman

Associate Professor in Surgery
Surgery, Surgical Sciences
Box 2606 Med Ctr, Durham, NC 27710
Research Drive, MSRBI Rm 414, Durham, NC 27710

Overview


My research interests encompass studies of immunity and inflammation in the context of developing and established cancers. These research interests involve studies of inflammation in the genesis and maintenance of specific cancer types (principally breast and ovarian), as well as the impact of inflammation on tumor metastasis and the tumor microenvironment.  My group is also involved in strategies to modulate the immune response to tumors, which involves the use of novel immunotherapeutic strategies and development of vaccines to specific oncogenic targets.  The major focus of my lab is in uncovering strategies to modulate tumor-derived inflammation and tumor-specific immunity that will translate into clinically efficacious therapies in patients.

Current Appointments & Affiliations


Associate Professor in Surgery · 2023 - Present Surgery, Surgical Sciences, Surgery
Associate Professor in Pathology · 2022 - Present Pathology, Clinical Science Departments
Associate Professor in Integrative Immunobiology · 2023 - Present Integrative Immunobiology, Basic Science Departments
Member of the Duke Cancer Institute · 2020 - Present Duke Cancer Institute, Institutes and Centers

In the News


Published May 9, 2023
Coffee Talk: Immunology and Breast Cancer
Published January 31, 2023
Duke Researchers use mRNA Vaccine Technology to Work on Cancer Vaccine
Published June 27, 2022
Clinical trial begins for Duke breast cancer vaccine.

View All News

Recent Publications


CD27 agonism enhances long-lived CD4 T cell vaccine responses critical for antitumor immunity.

Journal Article Sci Immunol · December 19, 2025 Tumor antigen vaccination represents an appealing approach for cancer but has failed to materialize as oncologic standard of care. To understand long-term vaccine efficacy, we conducted a retrospective analysis of patients with human epidermal growth recep ... Full text Link to item Cite

TuNa-AI: A Hybrid Kernel Machine To Design Tunable Nanoparticles for Drug Delivery.

Journal Article ACS Nano · September 23, 2025 Artificial intelligence (AI) has the potential to transform nanoparticle development for drug delivery; however, existing strategies typically optimize either material selection or component ratios in isolation. To enable simultaneous optimization of both, ... Full text Link to item Cite

Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd).

Journal Article Nat Commun · April 2, 2025 Trastuzumab deruxtecan (T-DXd) is an antibody-drug conjugate (ADC) targeting HER2, exhibiting significant clinical efficacy in breast cancer (BC) with varying HER2 expression, including HER2-low and HER2-ultralow. However, the precise mechanism underlying ... Full text Link to item Cite
View All Publications

Recent Grants


The Duke Preparing Research scholars In bioMEdical sciences (PRIME): Cancer Research Program

ResearchPreceptor · Awarded by National Cancer Institute · 2023 - 2028

Targeting dormancy-associated immune tolerance to eliminate residual breast cancer

ResearchMentor · Awarded by Department of Defense · 2025 - 2028

View All Grants

Education, Training & Certifications


Duke University · 2006 Ph.D.